Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy crawled time : 00:20 save search
Innovent Announces the Second Breakthrough Therapy Designation by NMPA for Olverembatinib for the Treatment of Patients with SDH-Deficient GIST
Published: 2023-06-02 (Crawled : 00:20) - prnewswire.com
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
treatment designation therapy
Global Vitamin D Therapy Market Report to 2029: Featuring Abbott, Sanofi, GlaxoSmithKline and Pfizer Among Others
Published: 2023-02-10 (Crawled : 00:20) - prnewswire.com
GSK | News | $41.24 1.6% 0.0% 2.3M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
| Email alert
Add to watchlist
GLAXF | News | $20.305 -14.18% 630
|
Health Technology
| Email alert
Add to watchlist
global report therapy market
Lysogene Provides Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study
Published: 2022-11-18 (Crawled : 00:20) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
| Email alert
Add to watchlist
topline therapy results study phase 2
Nektar and Collaborators Present Preclinical Data on NKTR-255, a Novel IL-15 Receptor Agonist, in combination with CAR Cell Therapies at the 2022 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®
Published: 2022-04-23 (Crawled : 00:20) - prnewswire.com
NKTR | News | $1.415 4.04% 3.89% 1.1M
|
Health Technology
| Email alert
Add to watchlist
nktr-255 cibmtr preclinical therapy pre-clinical
MIRASOL: A Randomized, Open-Label, Phase 3 Study of Mirvetuximab Soravtansine vs Investigator’s Choice of Chemotherapy in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor Alpha Expression
Published: 2022-03-19 (Crawled : 00:20) - immunogen.com
IMGN | News | $31.23 0.03% 49M
|
Health Technology
| Email alert
Add to watchlist
label one therapy cancer mirvetuximab phase 3
NextCure and Collaborators Provide Clinical and Research Updates on NC318 and NC410 Candidates at Society for Immunotherapy of Cancer Annual Meeting
Published: 2021-11-13 (Crawled : 00:20) - globenewswire.com
NXTC | $1.53 -4.97% -5.23% 90K
|
Health Technology
| Email alert
Add to watchlist
immunotherapy therapy cancer research
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Cancers at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Published: 2021-11-13 (Crawled : 00:20) - globenewswire.com
IOVA M | $11.86 4.77% 4.55% 3.9M
|
Health Technology
| Email alert
Add to watchlist
immunotherapy therapy cancer iot
Innovent Releases Interim Analysis Results of Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in the Phase 3 ORIENT-16 Study at ESMO Congress 2021
Published: 2021-09-18 (Crawled : 00:20) - prnewswire.com
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
| Email alert
Add to watchlist
treatment therapy results phase 3
Innovent Releases Interim Analysis Results of Sintilimab plus Chemotherapy for the First-Line Treatment of Esophageal Squamous Cell Carcinoma in the Phase 3 ORIENT-15 Study at ESMO Congress 2021
Published: 2021-09-18 (Crawled : 00:20) - prnewswire.com
INCY | $51.62 -0.58% -0.58% 2.5M
|
Health Technology
| Email alert
Add to watchlist
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
| Email alert
Add to watchlist
treatment therapy results phase 3 cell carcinoma
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.